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Abstract
Background: The treatment of hepatic metastases from gastric cancer is controversial, due to biologic aggressiveness of the disease.
Objective: To survey the clinical approach to the subset of patients presenting with metachronous hepatic metastases as sole site of recur-
rence after curative resection of gastric cancer, focusing on the results achieved by different therapies and to investigate the prognostic
factors of major clinical relevance.
Methods: Retrospective multi-center chart review evaluating 73 patients, previously submitted to D 2 gastrectomy for gastric cancer, who
developed exclusive hepatic recurrence. Prognostic factors related to the patient, to the gastric malignancy and its treatment, and to the
metastatic disease and its therapy were evaluated.
Results: Forty-five patients received supportive care, 17 were submitted to chemotherapy, and 11 to hepatic resection. Survival was inde-
pendently influenced by the variables T ( p¼ 0.019), N ( p¼ 0.05) and G ( p¼ 0.018) of the gastric primary and by the therapeutic approach
to the metastases ( p< 0.005). In particular, T4 gastric cancer, presence of lymph-node metastases and G3 tumor displayed a negative prog-
nostic value. Therapeutic approach to the metastases was the principal prognostic variable: 1, 2, and 3 years survival rates were 22.2%,
4.4% and 2.2%, respectively, for patients without specific treatment; 44.9%, 12.8% and 6.4% after chemotherapy ( p¼ 0.08) and
80.8%, 30.3% and 20.2% after surgical resection ( p< 0.001).
Conclusions: Our data suggest some clinical criteria that may facilitate selection of therapy for patients with hepatic recurrence after pri-
mary gastric cancer resection. The best survival rates are associated with surgical treatment, which should be chosen whenever possible.
 2008 Elsevier Ltd. All rights reserved.
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Introduction
Hepatic metastases are observed in about 50% of gastric
cancer patients during the course of the disease. Of those
who undergo gastric resection, 25e30% are eventually
diagnosed with metachronous hepatic metastases with an
equal distribution between those with exclusive hepatic re-
currence and those with concurrent extra-hepatic relapse.1,2
The positive results achieved by aggressive multidisci-
plinary approach to liver metastases from colorectal
cancer3,4 have not been reproduced in gastric cancer, seem-
ingly due to the biologic aggressiveness of the disease. Al-
though the possibility of prolonged survival has been
reported after resection of hepatic metastases, conditions
permitting a surgical approach seem to be a rare occur-
rence. A recent literature review reported only 229 cases,5
and a French survey recruited only 101 patients from 41
centres.6 However, it is also possible that such a low num-
ber of hepatectomies for metastases from gastric cancer,
arising from a few dedicated centres, also reflects a grim
and a priori passive attitude toward these patients.
Our study, a multi-center descriptive review, was de-
signed with two goals. The first was to survey the clinical
approach to the particular subset of patients presenting
with exclusive metachronous hepatic metastases after
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curative resection of gastric cancer, focusing on the results
achieved by different therapies. Our second purpose was to
identify prognostic factors of major clinical relevance,
since recognition of the cases with a better likelihood of
survival may promote a more positive therapeutic attitude.
Four university institutions displaying a standardized
surgical technique and a common follow-up protocol coop-
erated in this study, under the auspices of the Italian
Research Group for Gastric Cancer.
Patients and methods
Records of all gastric cancer patients submitted to cura-
tive (R0) D 2 gastrectomy during the period 1990e2004
in the 4 participating institutions were reviewed to identify
cases that developed metachronous hepatic metastases
without extra-hepatic relapse during follow-up. Patients
who developed synchronous metastases, presented with di-
rect infiltration of the liver, operated for carcinoma of the
gastric stump or had substantially incomplete records
were excluded.
We identified 73 patients, 52 men and 21 women, with
a mean age of 66 11 years at the time of gastric surgery.
All surgical specimens were examined accordingly to the
general rules of the JRSGC and scored according to the
1997 TNM system. After discharge, a follow-up protocol
was initiated. Post-gastrectomy adjuvant chemotherapy
was employed in 15 cases; the regimen most frequently se-
lected (8 cases) combined cisplatin, epirubicin, leucovorin
and 5-fluorouracil (PELF).7 Extent of hepatic recurrence
was classified according to the JRSGC: H1, liver metasta-
ses limited to one lobe of the liver; H2, isolate metastases
in both lobes of the liver; H3, multiple spread of metastases
in both lobes of the liver. This information was collected
from reports of appropriate imaging studies e ultrasound
(US) and/or CT with percutaneous biopsy e that allowed
the diagnosis of liver metastasis.
Therapeutic approach to the metastases was selected by
the different surgeons on the basis of personal attitude to-
ward these specific metastases, without any pre-set com-
mon criteria, in absence of institutional protocols or
guidelines. Possible treatments were best supportive care,
systemic chemotherapy and hepatectomy.
After the diagnosis of hepatic recurrence, patients pur-
sued dedicated follow-up schedules.
We evaluated how survival from diagnosis of liver recur-
rence was influenced by different parameters, selecting pos-
sible patient-related, gastric cancer-related, and hepatic
metastases-related prognostic factors. For patient-related
factors, we considered sex and age (the median age of 68
years was the cut-off). For gastric cancer-related factors,
we studied factors T and N of the TNM system, stage
(stages IIIb and IV were considered together), histological
type (Lauren classification) and grading, tumor location,
type of gastrectomy and adjuvant chemotherapy. For he-
patic metastases-related factors, we analyzed factor H,
disease-free interval between gastrectomy and diagnosis
of hepatic recurrence (using the median value of 11 months
as cut-off), and therapeutic approach to the metastases. A
bias of the covariates was evident when evaluating the ther-
apeutic approach to the metastases; in this case the compar-
ison was at first repeated excluding patients with H3
disease and subsequently considering only those affected
by 1 or 2 metastases of limited dimension (Ø 5 cm).
Statistical analysis
Fisher’s exact test (categorical variables) and Student’s
t-test (continuous variables) were employed to analyze dif-
ferences among groups. KaplaneMeier survival curves
were compared using the log-rank test. The independent
role of all variables showing a p 0.05 from univariate
analysis was analyzed by Cox model. A p value of 0.05
was considered significant. All analyses were performed
using SPSS 14.0 for Windows.
Results
The median follow-up after gastrectomy was 19 months
(5e175). Forty-two patients presented the liver recurrence
during the first 11 months after gastric resection and 31 af-
ter 12 months or more. Recurrence after more than 2 years
was rare (7 cases) but in 1 case the disease-free interval was
144 months.
Treatment groups
Similar lesions received different treatments in the dif-
ferent centres and, within each centre, treatments differed
during the study period. The retrospective nature of our
work hampered the recognition of criteria supporting the
therapeutic indication, especially when supportive care
was selected. However, all treated patients had a strong mo-
tivation for continuing therapies. Furthermore, the feasibil-
ity of a curative (R0) hepatic resection was the ultimate
indication for surgery; in these patients the favourable pre-
sentation was confirmed by CT 45e90 days after diagnosis.
Alternative treatments were decided by consensus between
surgical team and referring oncologist; hepatectomy was
never associated to neoadjuvant and/or adjuvant chemother-
apy. In all, 45 patients did not receive specific therapies, 17
were treated with chemotherapy, and 11 (15%) were sub-
mitted to surgery; the different treatments were evenly dis-
tributed during the study period.
The extent of liver involvement was the sole factor dis-
playing a significant difference among the different thera-
peutic strategies: H3 patients were systematically
excluded from surgery. Beside this point, patients in all 3
arms of treatment demonstrated similar characteristics,
with homogeneous distribution of the other candidate prog-
nostic factors.
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Different chemotherapy protocols were used in the par-
ticipating centres and, within each centre, they varied dur-
ing the study period; the PELF regimen8 was employed in
10 patients while different associations of 5-fluorouracil
and folic acid were employed in the remaining 7. Surgery
was pursued in 11 of 29 patients presenting 1 (8 cases) or
2 (3 cases) hepatic metastases of limited dimensions
(Ø 5 cm). Hepatic resections of varying extents were per-
formed: 5 non-anatomic resections, 3 segmentectomies, 2
bisegmentectomies and 1 right hepatectomy. In all cases
the resection was R0 and the procedure, conducted on nor-
mal liver also in the 3 patients who received the PELF pro-
tocol after gastrectomy, was reported as non-complicated.
The postoperative course was always uneventful. Median
follow-up after hepatectomy was 15 months (4e86).
Survival
At the final evaluation (January 2006), all but 5 patients
(7%) had died, the cause of death was related to cancer pro-
gression in 67 cases and to stroke in a disease-free patient
14 months after the resection of a liver metastasis. Hepatic
recurrence, in 3 cases associated with extra-hepatic sites of
relapse, caused the death of 7 resected patients. Hepatic re-
currence was reported as H3 in all but 2 patients presenting
a single metastasis which was left untreated. Three patients
who underwent surgical resection of hepatic metastases
were alive and disease-free 91, 60 and 9 months after diag-
nosis. Two patients presenting with bi-lobar metastases
treated with chemotherapy were alive after 7 and 36
months. Overall survival from the diagnosis of hepatic me-
tastases was 33%, 10%, 6% and 4% at 1, 2, 3 and 5 years,
respectively. Median survival was 7 months (1e91).
Prognostic factors
Statistical analysis (Table 1) showed that variables T
( p¼ 0.019), N ( p¼ 0.05) and G ( p¼ 0.018) of the gastric
primary and therapeutic approach to the metastases
( p¼ 0.005) displayed independent, significant associations
with survival. In particular, T4, Nþ (independent from the
extension of the metastatic spread -N1-3-) and G3 were as-
sociated with worse prognosis. As shown in Fig. 1, survival
drops in presence of any 1 of these factors. These factors
also show a cumulative effect, with mean survival of
42 12, 13 2, 8 1 and 3 1 months for patients pre-
senting with 0, 1, 2 or 3 risk factors, respectively
( p< 0.001). Considering the subset of cases affected by
H1 and H2 hepatic recurrence and left untreated, patients
presenting with 0 or 1 negative prognostic factors related
Table 1
Association of candidate prognostic variablesa with survival. Univariate and multivariate analysis.
n Survival % Univariate p Multivariate p Risk ratio (CI 95%)
1 year 2 years 3 years
Factors related to the patient
Sex M 52 37 14 8 0.049 N.S. e
F 21 24 0 0
Factors related to the gastric cancer and to its treatment
T 1 3 50 0 0 0.001 0.019 2.139 (1.132e4.043)
2 32 52 17 9
3 40 27 8 5
4 7 0 0 0
N þ 66 31 6.5 3 0.029 0.050 3.605 (0.997e13.033)
e 7 57 43 29
Stage I 4 67 67 33 0.022 N.S. e
II 20 45 10 5
IIIa 23 38 9 5
IIIbeIV 26 15 4 4
Grading 1e2 36 44 18 12 0.037 0.018 2.082 (1.186e3.656)
3 34 22 3 0
x 3
Factors related to the metastases and to their treatment
Extent of liver involvement H 1 23 51 14 9 0.061 e
H 2 17 41 18 6
H 3 33 16 3 3
Disease-free interval 11 months 42 28 8 0 0.044 N.S. e
>11 months 31 40 14 10
Treatment No treatment 45 22 4 2 <0.0001 0.005 0.629 (0.457e0.867)
Chemotherapy 17 45 13 6
Surgery 11 81 30 20
a Only variables displaying p< 0.1 at univariate analysis are shown.
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to the gastric primary had a longer survival than patients
with 2 or 3 risk factors (16 6 vs. 4 3 months,
p¼ 0.03), but similar patients submitted to hepatic resec-
tion performed far better (42 16 vs. 19 4 months, re-
spectively). In fact, multivariate analysis on the entire
population showed that therapeutic approach to the liver
metastases demonstrated the most powerful association
with survival, in particular (Fig. 2) when surgical resection
was performed ( p< 0.001); chemotherapy was associated
with possible survival benefit, albeit without statistical rel-
evance ( p< 0.08). It is worth of note that 22%, 4%, 2%,
and 0% of the patients without specific treatment were alive
after 1, 2, 3 and 5 years, respectively; at similar time-points
we observed a survival rate of 45%, 13%, 6%, and 0% after
chemotherapy, while surgical treatment compared favour-
ably with survival rates of 81%, 30%, 20% and 20%.
Median survival of non-treated patients was 5 months, in-
creasing to 12 if chemotherapy was employed and to 23
months after surgery. The significant relationship between
surgical treatment and prolonged survival was confirmed
when excluding H3 patients from statistical evaluation
( p¼ 0.0052) and when considering only the 29 patients
(Fig. 3) presenting with 1 or 2 small metastases at time
of diagnosis ( p¼ 0.026).
Discussion
Our survey confirms that the diagnosis of hepatic metas-
tases from gastric cancer is associated to poor prognosis,
that cases of long-term survivors are rare when hepatic
metastases occur, and that in our institutions a passive atti-
tude toward these patients prevailed, reflected by over 60%
of patients not receiving specific treatments, including 30%
of cases affected by 1 or 2 small metastases, and by
therapeutic indication being influenced by patients’ deter-
mination. However, after curative hepatectomy, we found
a 5-year survival rate of 20%, in agreement with existing
literature;9e15 furthermore, all survivors in our review,
including 3 of 4 long-term survivors, had undergone either
chemotherapy or surgical therapy.
Prognostic factors
Considering the aggressive biologic behaviour of gastric
cancer, recognition of cases that may benefit from treatment
can be critical. Various surgical series have demonstrated
that several clinical and pathological parameters correlate
with survival; among these, staging factors of the primary
tumor, extension of liver involvement, and disease-free in-
terval have been reported more often than others.6,9e21 The
French school,22 strongly suggested that use of prognostic
factors can appropriately select patients for surgical inter-
vention. Interestingly, however, analysis of long-term survi-
vors reported in the literature also shows that, if we exclude
cases presenting a bi-lobar spread of metastases, none of
the reported predictive factors e alone or in combination e
can deprive a patient of the possibility of a long-term
Figure 1. Cumulative survival according to the number of negative prog-
nostic factors related to the gastric primary (T4, Nþ, G3). Log-rank test
p¼ 0.001.
Figure 2. Cumulative survival related to the therapeutic approach to the
metastases. Median survival: 5 months (CI 95%: 3e7) without treatment,
12 months (CI 95%: 6e17) after chemotherapy, 23 months (CI 95%:
9e37) after surgery. Log-rank tests: surgery vs. no treatment p< 0.001;
chemotherapy vs. no treatment p¼ 0.08; surgery vs. chemotherapy
p¼ 0.096.
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survival after the hepatic resection,5 raising concern about
the clinical value of prognostic factors emerging from su-
per-selected populations.
Our data, from an entirely unselected cohort of patients
presenting an hepatic relapse, show that the factors T, N
and G of the gastric primary, when rated T4, Nþ and G3,
independently display a clear negative prognostic value.
Our analysis also shows that patients with no more than 1
negative prognostic factor experienced a more favourable
course of the disease. These patients should, whenever pos-
sible, be referred to the surgeon. In fact, therapeutic ap-
proach seems to be the most important variable
influencing prognosis: in our experience hepatectomy was
associated with a five-fold increase in survival of the less-
favourable patients (>1 negative prognostic factor) and
achieved an overall 5-years survival rate of 20%. The
more favourable stage of surgical patients may explain
the recorded difference in survival but, remarkably, the ben-
eficial effect of surgery proved to be sound not only when
the entire population was considered, but also when the
analysis was restricted to patients presenting with relatively
favourable hepatic involvement (H1 and H2) and, in partic-
ular, to the subgroup of patients presenting with minimal
hepatic involvement (1 or 2 small lesions).
Treatment of hepatic metastases
Resection of liver metastases from gastric cancer is indi-
cated in absence of extra-hepatic recurrence,10 if a complete
resection of the metastases can be achieved while
preserving postoperative liver function.16 In these
conditions hepatectomy is a low-risk procedure, with low
mortality and morbidity rates. It should also be noted that
the surgical treatment does not impair life expectancy,
even in cases when the ideal technical criteria e such as
the resection margin e are not strictly adhered-to.
In our experience, adjuvant chemotherapy after gastrec-
tomy did not negatively affect survival after hepatic relapse,
implying that recurrence in these cases does not necessarily
reflect more aggressive disease. A trend toward a better sur-
vival was also observed in patients with recurrence treated
with chemotherapy. Absence of a common protocol in the
participating centres hampered our study in evaluating
true effects of chemotherapy. However, since our protocols
probably do not represent actual gold standard for gastric
cancer, appropriate chemotherapy may be associated with
greater survival improvement than that seen in our patients.
Despite therapy, these patients generally die because of
cancer progression, whether within the liver or in extra-he-
patic sites. This observation raises concern about the timing
of treatment, in particular when surgical resection is
planned, in order to avoid inappropriate operations. In our
experience surgical indication was dependent on a delayed
CT confirmation of the favourable hepatic involvement, but
the French colleagues22 suggest a systematic multidisci-
plinary approach; in this setting, systemic chemotherapy
should be promptly started whenever possible, in order to
offer its advantages to a greater number of patients and to
effectively select cases for surgery. These attitudes would
motivate vigilant follow-up protocols, at least for the first
2 years following gastrectomy, especially in cases at high
risk of cancer recurrence,23,24 considering that during this
period over 90% of recurrences can be detected and that
early presentation of hepatic metastases is not a negative
prognostic factor.
Conclusion
In conclusion, we observed that simple clinical and bio-
logical characteristics of the gastric primary display prog-
nostic value which may be helpful in selecting
therapeutic strategy when the diagnosis of hepatic recur-
rence is made. We also observed that the best results are as-
sociated with surgery, which, in patients with appropriate
risk factor status, should be proposed whenever possible.
We are conscious that our data have to be viewed with cau-
tion, considering the nature of our survey. However, we be-
lieve that our findings have a role in encouraging
a pragmatic attitude toward patients with exclusive hepatic
metastatic disease after primary gastric resection and in
promoting surgery, at least in the most favourable cases.
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